Our Stories

Our Stories

트위터 링크드

31/12/2021 2021 Year in Review: Our Top 5 Highlights


2021 has been another challenging yet incredible year for Samsung Bioepis. As 2021 comes to a close, we would like to take this time 
to reflect on some of our key highlights and achievements we have made. Here we present our top 5 highlights of the year that 
our hard-working colleagues demonstrated our passion for health and commitment. 


1) Opened Samsung Bioepis’ State-of-the-Art Headquarters
Samsung Bioepis kicked off the new year in the new place. In January, we moved into our state-of-the art headquarters in Korea’s ‘Bio Cluster’ of Songdo, Incheon. The opening of the headquarters enabled all of Samsung Bioepis’ colleagues to work together at the same site, shifting away from working at two campuses in Korea previously. The headquarters are now served as the foundation of the company’s next stage of growth and offer diverse work settings, which is equipped with spacious laboratory space and office space, as well as a fitness center, cafeteria and a child daycare center.  

2) Celebrated 9th Anniversary for Continued Innovation 
On February 28th, Samsung Bioepis celebrated the 9th anniversary for the continued innovation and our journey to becoming a leading biopharmaceutical company. With only one-year shy of the 10-year anniversary milestone, our Chief Executive Officer and President Christopher Hansung Ko shared a message of gratitude for all who have been a part of the journey and looked forward to our growth together. In celebration of our anniversary, our colleagues also made mask kits that were donated to more than 10,000 local elementary students.

3) Won two iF Design Awards for Patient-centricity and Design Originality
Samsung Bioepis received two awards at the world-renowned International Forum (iF) Design Award 2021 for its brand identity, marking our second international design award win. At the iF Design Award, Samsung Bioepis won two categories: Packaging - Medicine/Pharmaceutics and Communication - Corporate Identity/Branding. The winning design, titled ‘Passion for Health: Pure Joy in Life,’ was inspired by tranquility of nature and organic forms in life. In 2020, we also won Red Dot Awards for the same brand identity in two categories: Brand Design & Identity and Packaging Design.
 
4) Achieved Regulatory Milestones with Ophthalmology Biosimilar
On our regulatory front, Samsung Bioepis reached milestones with gaining approvals for our ophthalmology biosimilar from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, in 2021. This underscores Samsung Bioepis’ commitment to find smarter, faster ways of getting high-quality medicines to the people who need them the most. We will continue to advance and broaden our pipeline of biosimilar candidates which now covers a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology. 

5) Released First Annual Sustainability Report 
Our last and important highlight of the year was releasing our very first annual sustainability report. The report outlines our Environment, Social and Governance (ESG) performance and commitment to becoming a more socially responsible and sustainable company. It offers a comprehensive overview of Samsung Bioepis’ efforts across the three pillars of sustainability and commitment to developing long- term ESG initiatives which will be navigated by a dedicated ESG team going forward.

Looking ahead to 2022, Samsung Bioepis will continue to build on this momentum and keep pushing ourselves to the next level of growth and innovation. 
more
SAMSUNG BIOEPIS

확인 취소
레이어 팝업 닫기